Abstract
BackgroundPrenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. However, its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown.MethodsPRAF2 mRNA expression was determined in 77 frozen ESCC samples by quantitative reverse transcription-polymerase chain reaction (qPCR) and its association with clinical features and overall survival were evaluated. The roles of PRAF2 in ESCC cells were investigated by proliferation, cell cycle, invasion and apoptosis assays in vitro.ResultsThe PRAF2 mRNA expression was significantly increased in ESCC tissues compared with matched surrounding non-tumor tissues. Survival analysis showed that high PRAF2 mRNA expression was associated with worse overall survival in ESCC patients. Multivariate analysis revealed that PRAF2 (hazard ratio 2.05, 95% CI 1.10–3.85, P = 0.025) emerged as the independent predictor for poor overall survival in ESCC. The in vitro experiments revealed that knockdown of PRAF2 expression blocked cell proliferation, cell cycle progression and cell invasion and induced cell apoptosis in ESCC cells.ConclusionTaken together, our data demonstrate that PRAF2 could be used as a potential prognostic biomarker and represent a potential therapeutic target for ESCC.
Highlights
Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors
PRAF2 were up-expressed in squamous cell carcinoma but not in adenocarcinoma tissues compared to normal tissues (Fig. 1a, P = 0.027)
PRAF2 mRNA expression was markedly elevated in cancer tissues compared with non-cancerous normal tissues (Fig. 1b)
Summary
Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. Its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown. About 90% of esophageal cancers are esophageal squamous cell carcinoma (ESCC) on pathological examination [3]. Further elucidation of the molecular events in ESCC development may yield alternative means for the management of ESCC [6, 7]. Prenylated Rab acceptor 1 domain family, member 2 (PRAF2, called JM4), a 178 amino acid endoplasmic reticulum (ER)-resident protein, comprise a prenylated. PRAF2 has been considered as oncogene since it is highly expressed in multiple tumor tissues of the breast, colon, lung and ovary cancer [10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
